Prof. Jinming Yu 于金明
Chief Physician, Professor
Department of Thoracic Radiation Oncology I, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionCurrent positions:Academician, Chinese Academy of Engineering; President, Shandong Cancer Hospital
Checked against a public report (2026-09). Positions change; the hospital's website is the final word.
Clinical focus: Clinical focus on tumor radiation therapy, including stereotactic, conformal, intensity-modulated, and image-guided techniques.
Dr. Yu is an Academician of the Chinese Academy of Engineering and Director of Shandong Cancer Hospital. With a doctorate in radiology and five years of experience in the US, Dr. Yu has worked in oncology since 1983. Research interests include precise radiotherapy and molecular imaging. Dr. Yu has received the National Science and Technology Progress Award.
Professional roles
- Former Chair, Radiation Oncology Committee, Chinese Medical Association
- Chair, Radiotherapy Committee, China Anti-Cancer Association
- Chair, Shandong Anti-Cancer Association
- Editor-in-Chief, Chinese Journal of Cancer Prevention and Treatment
Name order: in Chinese the family name comes first (Yu Jinming). Papers usually list the name as Jinming Yu or Yu J.
Selected publications
742 papers on PubMed matched by name and affiliation; 36 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cancer Metastasis Rev, 2026 (senior author): Circulating Cell-free DNA as a biomarker for radiation-induced injury: From mechanistic insights to clinical translation. PubMed 42747547
- Chin J Cancer Res, 2026 (senior author): Radiation oncology at a new frontier: Hotspots, challenges, and emerging advances. PubMed 42713099
- Chem Biomed Imaging, 2026 (senior author): (18)F‑CC-Omi‑X PET in Characterizing Lipid Metabolism via ACE2 Mapping. PubMed 42656956
- Ther Adv Med Oncol, 2026 (senior author): Association of salvage radiotherapy with survival outcomes in extracranial oligoprogression after first-line therapy for extensive-stage small-cell lung cancer: a multicenter retrospective cohort study. PubMed 42504316
- Chin J Cancer Res, 2026 (senior author): Preface to Special Issue: Breakthroughs in malignancy therapy: New advances and emerging trends. PubMed 42421906
- QJM, 2026 (senior author): Treatment-Related Cardiotoxicity in Non-Small Cell Lung Cancer: A Population-Based Analysis for Risk Stratification. PubMed 41883157
- Am J Cancer Res, 2026 (senior author): Restoring osimertinib sensitivity in EGFR-mutant NSCLC: the role of anlotinib in modulating Wnt/β-catenin/YAP pathways. PubMed 41657791
- Cancer Lett, 2025 (senior author): A multicenter, real-world study analysis: pembrolizumab changes treatment strategy for the patient with recurrent/metastatic head and neck squamous cell carcinoma. PubMed 40846296
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion